![1-β-d-Arabinofuranosylcytosine-5′-alkylphosphonophosphates and diphosphates: new orally active derivatives of ara-C - Journal of Lipid Research 1-β-d-Arabinofuranosylcytosine-5′-alkylphosphonophosphates and diphosphates: new orally active derivatives of ara-C - Journal of Lipid Research](https://www.jlr.org/cms/asset/ee1bbe0d-546c-4e63-917c-0b933ac7dd97/gr1.jpg)
1-β-d-Arabinofuranosylcytosine-5′-alkylphosphonophosphates and diphosphates: new orally active derivatives of ara-C - Journal of Lipid Research
![Cytarabin (Cytosinarabinosid, Ara-C)-Chemotherapie-Arzneimittelmolekül. Zur Behandlung der: Stock-Vektorgrafik (Lizenzfrei) 2050245218 | Shutterstock Cytarabin (Cytosinarabinosid, Ara-C)-Chemotherapie-Arzneimittelmolekül. Zur Behandlung der: Stock-Vektorgrafik (Lizenzfrei) 2050245218 | Shutterstock](https://www.shutterstock.com/shutterstock/photos/2050245218/display_1500/stock-vector-cytarabine-cytosine-arabinoside-ara-c-chemotherapy-drug-molecule-used-in-treatment-of-acute-2050245218.jpg)
Cytarabin (Cytosinarabinosid, Ara-C)-Chemotherapie-Arzneimittelmolekül. Zur Behandlung der: Stock-Vektorgrafik (Lizenzfrei) 2050245218 | Shutterstock
![PDF) High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: Long-term results of the German AMLCG PDF) High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: Long-term results of the German AMLCG](https://i1.rgstatic.net/publication/26800052_High_dose_ara-C_in_the_treatment_of_newly_diagnosed_acute_promyelocytic_leukemia_Long-term_results_of_the_German_AMLCG/links/00b7d53b3bb957411c000000/largepreview.png)
PDF) High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: Long-term results of the German AMLCG
![Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signaling | Cell Communication and Signaling | Full Text Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signaling | Cell Communication and Signaling | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12964-018-0317-z/MediaObjects/12964_2018_317_Fig5_HTML.png)
Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signaling | Cell Communication and Signaling | Full Text
![Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C | Leukemia Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C | Leukemia](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fsj.leu.2403157/MediaObjects/41375_2003_Article_BF2403157_Fig2_HTML.gif)
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C | Leukemia
Randomisierter Vergleich zwischen Standard- und intensivierter Therapiestrategie der akuten myeloischen Leukämie des Erwachsene
![PDF) Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/ macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: Final results of PDF) Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/ macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: Final results of](https://i1.rgstatic.net/publication/7611563_Low-dose_cytosine_arabinoside_LD-AraC_vs_LD-AraC_plus_granulocyte_macrophage_colony_stimulating_factor_vs_LD-AraC_plus_Interleukin-3_for_myelodysplastic_syndrome_patients_with_a_high_risk_of_developin/links/00b495346fa25f2c4d000000/largepreview.png)
PDF) Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/ macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: Final results of
![Set Von Erwachsenen Papagei Von Rotgrünen Ara Ara Cartoon Vogel Design Flache Vektorillustration Isoliert Auf Weißem Hintergrund Stock Vektor Art und mehr Bilder von Papagei - iStock Set Von Erwachsenen Papagei Von Rotgrünen Ara Ara Cartoon Vogel Design Flache Vektorillustration Isoliert Auf Weißem Hintergrund Stock Vektor Art und mehr Bilder von Papagei - iStock](https://media.istockphoto.com/id/1203396781/de/vektor/set-von-erwachsenen-papagei-von-rot-gr%C3%BCnen-ara-ara-cartoon-vogel-design-flache-vektor.jpg?s=612x612&w=0&k=20&c=mnqWP0UfcrL9HXHdaPG6saBf5ovXhJP-9B6P7IFrFK4=)
Set Von Erwachsenen Papagei Von Rotgrünen Ara Ara Cartoon Vogel Design Flache Vektorillustration Isoliert Auf Weißem Hintergrund Stock Vektor Art und mehr Bilder von Papagei - iStock
![Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML) | springermedizin.de Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML) | springermedizin.de](https://media.springernature.com/lw400/springer-static/cover/journal/277/79/1.jpg?as=jpg)
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML) | springermedizin.de
![P Langen's research works | Max-Delbrück-Centrum für Molekulare Medizin, Berlin (MDC) and other places P Langen's research works | Max-Delbrück-Centrum für Molekulare Medizin, Berlin (MDC) and other places](https://www.researchgate.net/publication/13760486/figure/fig2/AS:981675488059392@1611061083670/Dose-dependent-growth-inhibition-induced-by-ara-C-and-ara-C-phospholipid-conjugates-1-4_Q320.jpg)